923 related articles for article (PubMed ID: 1533383)
1. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
Enk L; Landgren BM; Lindberg UB; Silfverstolpe G; Crona N
Horm Metab Res; 1992 Feb; 24(2):85-9. PubMed ID: 1533383
[TBL] [Abstract][Full Text] [Related]
2. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
3. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.
Westhoff C
J Reprod Med; 1996 May; 41(5 Suppl):401-6. PubMed ID: 8725702
[TBL] [Abstract][Full Text] [Related]
4. [Injectable contraceptive, DMPA, serum HDL cholesterol and heart infarct].
Kremer J; de Bruijn HW; Hindriks FR
Ned Tijdschr Geneeskd; 1981 Aug; 125(35):1418-21. PubMed ID: 6456421
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the effects of two once-a-month injectable steroidal contraceptives (Mesigyna and Cyclofem) on lipid and lipoprotein metabolism. United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank, Special Programme of Research, Development and Research Training in Human Reproduction.
Contraception; 1997 Oct; 56(4):193-207. PubMed ID: 9408700
[TBL] [Abstract][Full Text] [Related]
6. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.
Victor A; Lithell H; Selinus I; Vessby B
Ups J Med Sci; 1984; 89(2):179-88. PubMed ID: 6380076
[TBL] [Abstract][Full Text] [Related]
8. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
[TBL] [Abstract][Full Text] [Related]
9. Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile.
Fahmy K; Abdel-Razik M; Shaaraway M; al-Kholy G; Saad S; Wagdi A; al-Azzony M
Contraception; 1991 Oct; 44(4):419-30. PubMed ID: 1836754
[TBL] [Abstract][Full Text] [Related]
10. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
[TBL] [Abstract][Full Text] [Related]
11. The effect of injectable contraceptive on lipid metabolism in women.
Kandeel KM; Nayel SA; Abaza MS
Biomed Biochim Acta; 1984; 43(1):111-5. PubMed ID: 6721873
[TBL] [Abstract][Full Text] [Related]
12. The effect of contraceptive steroids on plasma lipoprotein metabolism in female rats (II).
Köse K; Doğan P; Ozesmi C
Biochem Mol Biol Int; 1993 Jun; 30(2):245-52. PubMed ID: 8364406
[TBL] [Abstract][Full Text] [Related]
13. Effect of administration and withdrawal of oral contraceptive pills on serum lipids and lipoproteins.
Arora S; Arora RC; Garg RK; Agarwal N; Nautiyal A
Indian J Physiol Pharmacol; 1988; 32(1):67-71. PubMed ID: 3169963
[TBL] [Abstract][Full Text] [Related]
14. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
[TBL] [Abstract][Full Text] [Related]
15. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins.
Odmark IS; Bäckström T; Haeger M; Jonsson B; Bixo M
Maturitas; 2004 Jun; 48(2):137-46. PubMed ID: 15172088
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism.
Garza-Flores J; De la Cruz DL; Valles de Bourges V; Sanchez-Nuncio R; Martinez M; Fuziwara JL; Pérez-Palacios G
Contraception; 1991 Jul; 44(1):61-71. PubMed ID: 1832626
[TBL] [Abstract][Full Text] [Related]
17. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
[TBL] [Abstract][Full Text] [Related]
18. Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections.
Canto de Cetina TE; Luna MO; Cetina Canto JA; Bassol S
Contraception; 2004 Feb; 69(2):115-9. PubMed ID: 14759615
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception.
Beksinska ME; Smit JA; Kleinschmidt I; Farley TM; Mbatha F
Contraception; 2005 Mar; 71(3):170-5. PubMed ID: 15722065
[TBL] [Abstract][Full Text] [Related]
20. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
